• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

by Elena Iemma | Oct 11, 2022

Poster: Innovative preclinical assessment tools for safety and efficacy of protein and peptide therapeutics… Of Peptides and P-ANDAS

Poster: Innovative preclinical assessment tools for safety and efficacy of protein and peptide therapeutics… Of Peptides and P-ANDAS

by Elena Iemma | Sep 22, 2022

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics… of Peptides and P-ANDAS
Novel H7N9 influenza immunogen design enhances mobilization of seasonal influenza T cell memory in H3N2 pre-immune mice

Novel H7N9 influenza immunogen design enhances mobilization of seasonal influenza T cell memory in H3N2 pre-immune mice

by Elena Iemma | Jun 16, 2022

Novel H7N9 influenza immunogen design enhances mobilization of seasonal influenza T cell memory in H3N2 pre-immune mice

POSTER: Immune Tolerance Adjusted Personalized Immunogenicity Prediction for Rare Diseases

by Elena Iemma | May 30, 2022

Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetii Immunity

Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetii Immunity

by Elena Iemma | May 24, 2022

Next Entries »

Recent Posts

  • Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy
  • BEBPA Workshop: Streamlining Immunogenicity Assessment of Host Cell Proteins

Recent Comments

  1. Homepage on Doing Well and Giving Back in December

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.